Show simple item record

dc.contributor.authorFindlow, Jamieen_US
dc.contributor.authorTaylor, Stephenen_US
dc.contributor.authorAase, Audunen_US
dc.contributor.authorHorton, Rachelen_US
dc.contributor.authorHeyderman, Roberten_US
dc.contributor.authorSouthern, Joen_US
dc.contributor.authorAndrews, Nick J.en_US
dc.contributor.authorBarchha, Ritaen_US
dc.contributor.authorHarrison, Ewanen_US
dc.contributor.authorLowe, Annen_US
dc.contributor.authorBoxer, Emmaen_US
dc.contributor.authorHeaton, Charlotteen_US
dc.contributor.authorBalmer, Paulen_US
dc.contributor.authorKaczmarski, Eden_US
dc.contributor.authorOster, Philippen_US
dc.contributor.authorGorringe, Andrewen_US
dc.contributor.authorBorrow, Rayen_US
dc.contributor.authorMiller, Elizabethen_US
dc.description.abstractThe prediction of efficacy of Neisseria meningitidis serogroup B (MenB) vaccines is currently hindered due to the lack of an appropriate correlate of protection. For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined by the serum bactericidal antibody (SBA) assay and OMV enzyme-linked immunosorbent assay (ELISA). However, the opsonophagocytic assay (OPA), surface labeling assay, whole blood assay (WBA), and salivary antibody ELISA have been developed although correlation with protection is presently undetermined. Therefore, the aim of the study was to investigate further the usefulness of, and relationships between, MenB immunologic assays. A phase II trial of the OMV vaccine, MenBvac, with proven efficacy was initiated to compare immunologic assays incorporating the vaccine and six heterologous strains. Correlations were achieved between the SBA assay, OMV ELISA, and OPA using human polymorphonuclear leukocytes and human complement but not between an OPA using HL60 phagocytic cells and baby rabbit complement. Correlations between the surface labeling assay, the SBA assay, and the OMV ELISA were promising, although target strain dependent. Correlations between the salivary antibody ELISA and other assays were poor. Correlations to the WBA were prevented since many samples had results greater than the range of the assay. The study confirmed the immunogenicity and benefit of a third dose of MenBvac against the homologous vaccine strain using a variety of immunologic assays. These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease.en_US
dc.publisherAmerican Society for Microbiologyen_US
dc.publisher.placeUnited Statesen_US
dc.relation.ispartofjournalInfection and Immunityen_US
dc.subject.fieldofresearchImmunology not elsewhere classifieden_US
dc.titleComparison and Correlation of Neisseria meningitidis Serogroup B Immunologic Assay Results and Human Antibody Responses following Three Doses of the Norwegian Meningococcal Outer Membrane Vesicle Vaccine MenBvacen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Peer Reviewed (HERDC)en_US
dc.type.codeC - Journal Articlesen_US
gro.hasfulltextNo Full Text

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record